<Anchor> As



several types of corona vaccines have been developed and people start getting hit, studies are continuing to compare the effectiveness of the vaccines. In some studies, the higher the amount of neutralizing antibodies in the body after being vaccinated, the better the vaccine was, but we checked whether it was correct.



Medical reporter Yoo Seung-hyun will deliver this information



<Reporter>



Recently, an Australian research team compared the performance of seven different vaccines: Modena, Pfizer AstraZeneca, and Janssen.



The criterion was the amount of neutralizing antibodies produced after one shot of the vaccine.



Modena was the most common, four times the level of the cure for Corona 19, followed by NovaVax and Pfizer.



AstraZeneca and Janssen were ranked 5th and 6th, but they were less in the amount of neutralizing antibodies in the cure.



However, it is unreasonable to evaluate the efficacy of a vaccine only with the amount of neutralizing antibody.



[Ki-Jong Hong / Editor-in-Chief of the Korean Vaccine Society: '90 is better than 80 unconditionally?' It's hard to see like that. (Neutralizing antibody) It is premised that it can work if it exceeds the set standard.] When the



vaccine is given, antibodies are produced, but the virus does not enter the cells.



As important as antibodies are activated immune cells, which kill viruses that have entered the cells.



Immune cell activity is three times higher for AstraZeneca than Pfizer.



Neutralizing antibodies have more Pfizer, and activated immune cells have more AstraZeneca. How did it actually work?



This is the largest and most up-to-date data released by UK health officials on the 14th. The preventive effects of Pfizer and AstraZeneca were the same for people aged 65 and over.



The important thing is to get two vaccinations, but if you get two shots than once, the corona infection rate has decreased by more than three times, like Pfizer or AstraZenecana.



In a recent study, two doses of both vaccines have been shown to be more than 80% effective against mutations in the UK and South Africa.



(Video coverage: Gong Jin-gu, video editing: So Ji-hye)